GLP-1 Market
LLY $1149.85 ▼ -0.6% NVO $37.40 ▼ -1.3% PFE $28.12 ▼ -1.4% VKTX $30.51 ▼ -6.4% KLRA $11.03 ▼ -3.4% GPCR $28.98 ▼ -7.3% RHHBY $52.35 ▲ +0.9%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Elecoglipron

Company
AstraZeneca
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
10 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

10 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 2, 2026

Find a Clinical Trial Near Me

See recruiting studies for Elecoglipron and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07662044

    A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

    Not yet reported AstraZeneca 800 participants Est. completion 2028-07-14 149 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Recruiting NCT NCT07662109

    A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

    Not yet reported AstraZeneca 2000 participants Est. completion 2028-07-05 272 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Recruiting NCT NCT07662135

    A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

    Not yet reported AstraZeneca 900 participants Est. completion 2028-07-13 186 sites Stand-alone
    Type 2 diabetesChronic kidney disease
    View official trial listing →
  • Recruiting NCT NCT07662213

    A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

    Not yet reported AstraZeneca 1200 participants Est. completion 2028-05-23 209 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Recruiting NCT NCT07664553

    A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin

    Not yet reported AstraZeneca 600 participants Est. completion 2028-05-23 132 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Recruiting NCT NCT07667803

    A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

    Not yet reported AstraZeneca 4500 participants Est. completion 2029-07-30 325 sites Stand-alone
    Other conditions: Weight Management
    View official trial listing →
  • Recruiting NCT NCT07723833

    A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants

    Not yet reported AstraZeneca 152 participants Est. completion 2026-11-18 2 sites Stand-alone
    Other conditions: Healthy Participants
    View official trial listing →
  • Recruiting NCT NCT07753993

    A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

    Not yet reported AstraZeneca 7000 participants Est. completion 2030-10-04 715 sites Stand-alone
    Chronic kidney disease
    View official trial listing →
  • Recruiting NCT NCT07761117

    A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

    Not yet reported AstraZeneca 6950 participants Est. completion 2029-09-03 679 sites Stand-alone
    Heart failure
    View official trial listing →
  • Recruiting NCT NCT07775404

    A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus

    Not yet reported AstraZeneca 351 participants Est. completion 2028-04-13 49 sites Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Active, not recruiting NCT NCT07534592

    A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants

    Not yet reported AstraZeneca 48 participants Est. completion 2026-10-01 2 sites Stand-alone
    Other conditions: Healthy Participants
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.